New implant combo aims to lower eye pressure without daily drops
NCT ID NCT06066645
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a travoprost drug implant (iDose TR) plus a tiny stent (iStent infinite) can lower eye pressure better than the implant alone in people with open-angle glaucoma or high eye pressure. About 150 adults will receive either the combo or a sham procedure and be followed for 12 months. The goal is to see if the combo provides a longer-lasting pressure drop.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Travoprost intraocular implant (iDose TR) plus iStent infinite device
What this could lead to
If successful, this combination could offer a more effective, long-lasting way to lower eye pressure and reduce the need for daily eye drops in glaucoma patients.
What could go wrong
This is a Phase 4 trial with only 150 participants, so results may not apply to everyone. Risks include eye irritation, infection, or the implant not working as expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Glaukos Clinical Study Site
RECRUITINGOklahoma City, Oklahoma, 73112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••